You are here

Oncology Imaging

 

Five years ago the American Society of Clinical Oncology (ASCO) advised clinicians not to order advanced imaging or tumor marker tests for survivors of early-stage breast cancer. Yet the exam orders keep coming.

Reviewing brain MRI of close to 4,000 children as part of an ongoing population-based study, European neuroradiologists and neuroscientists discovered at least one incidental finding in more than one-quarter of the cohort.

The National Academy of Medicine announced Monday, Oct. 17, that it elected 80 new members, including Deborah Watkins Bruner, RN, PhD, a professor of radiation oncology at Emory University in Atlanta. 

A single 90-minute examination designed to assess chemotherapy-induced injuries of the brain, heart and joints among childhood cancer survivors has been proven feasible by a new study.

Starting annual screening mammography for breast cancer at age 40 helps detect a significant number of cancers, according to a recent study published in the American Journal of Roentgenology.

 

Recent Headlines

Whole body PET/CT finds some tricky cancers better than CT alone

Danish researchers have found whole body PET/CT augmented by the radiotracer FDG is superior to straight CT as a first-line modality for imaging patients with serious non-specific symptoms and signs of cancer (NSSC). Their study was published online Jan. 12 in the Journal of Nuclear Medicine.

Lung cancer screening guidelines stirred up something of a Twitter storm

Tweets about lung cancer screening multiplied markedly after the U.S. Preventive Services Task Force released its guidelines on screening with low-dose chest CT (LDCT) in December 2013, according to an analysis published online Jan. 13 in the Journal of Digital Imaging.

Experimental CAD system bests other diagnostic methods at catching lung cancer

Japanese researchers have developed a new a computer-aided diagnosis (CADx) system that’s superior to some other methods, relatively easy to use and capable of differentiating between malignant and benign nodules on lung CT.

Most interval lung cancers missed at NLST screening

A retrospective analysis of National Lung Screening Trial (NLST) exams has shown that most lung cancers that were detected within a year after a negative CT screening exam—some 40 of 44, or 91 percent—were present but overlooked at the screening. 

Watch for PET/CT to grow as an aid to image-guided biopsies of children

PET/CT can add value to cancer staging and follow-up in pediatric patients. In fact, it may come to play an important role in directing image-guided biopsies of children, according to a study published online Dec. 27 in the American Journal of Roentgenology.

CT is effective in staging colon cancer—with minor drawbacks

A retrospective study published in the American Journal of Roentgenology determined that CT is a useful tool for staging colon cancers that have moved beyond the bowel wall. While performance suffers in certain situations, the largely Dutch authors recommend using thin-slice CT to detect cancers.

 
5 reasons radiologists should reserve a seat on the tumor board

Radiologists who interpret oncologic imaging exams but don’t participate in multidisciplinary tumor boards (MTBs) miss a golden opportunity to show their value to clinicians, patients and provider systems. 

Ablation may be effective in battling small-cell lung cancer

Researchers from Brown University touted the efficacy of tumor ablation in treating small-cell lung cancer, publishing their results in the Journal of Vascular and Interventional Radiology.

 
Prostate cancer patients keep options open with MRI-guided interventions

MRI-guided prostate interventions appear to have a bright future combining with the latest and greatest radiation therapy techniques to make prostatectomy and no therapy at all the least attractive options for most men with low-to-intermediate-grade prostate cancer. 

ASTRO: Upped-dose radiation regimen maintains high quality of life for busy prostate cancer patients

BOSTON—Compared with conventional radiation therapy (RT), larger-dose RT delivered over a shorter period—called hypofractionated RT—has previously proven just as efficacious for treating low-risk, early-stage prostate cancer. Now researchers have further shown that, despite the increased doses, hypofractionated treatments do no clinically significant harm to these patients’ quality of life (QOL). 

Pages